A new study has uncovered new genetic rules that determine how CD8 “killer” T cells choose between becoming long-lasting, protective immune cells or slipping into exhausted, dysfunctional states.
CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures and a pioneer in synthetic biology, today announces the successful defence of its foundational European ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company's CRISPR-based ...
(a) Schematic of the in vivo CAR-T cell therapy process; (b) Clinically validated delivery platforms including LNP-based systems and viral vectors; (c) Emerging future directions for durable and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results